Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of exposure and response prevention in obsessive-compulsive disorder
NL-OMON33819Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of d-cycloserine in obsessive compulsive disorder (OCD), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in Yale-Brown Obsessive Compulsive Scale, Time of onset of change on the Yale-Brown Obsessive Compulsive Scale and 1 more. Planned start Apr 2009; status: not yet recruiting.
02
Drugs
d-cycloserine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NL-OMON33819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33819.